Shots:

• The P-IIb/III (ANAVEX 2-73-AD-004) evaluating ANAVEX 2-73 vs PBO in a ratio (1:1:1) in 509 patients with early AD over 48wks.
• The trial met its 1EPs & 2EPs i.e., reduction in the clinical decline of cognitive & functional scales as measured by ADAS-Cog, ADCS-ADL & CDR-SB (27% reduction in the ITT population) with visible improvement, 84% improved cognition by ADAS-Cog score change, 167% improved function by ADCS-ADL score change, 45% reduction in cognitive decline by ADAS-Cog, was safe & well tolerated

• The incidence of TEAEs was similar with no changes in vital signs, laboratory values & ECG parameters. The safety results were consistent with the known safety profile of ANAVEX 2-73. The company plans to submit the results to a peer-reviewed medical journal

Ref: Globenewswire | Image: Anavex